127 related articles for article (PubMed ID: 37721615)
21. Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship.
Cai T; Verze P; Brugnolli A; Tiscione D; Luciani LG; Eccher C; Lanzafame P; Malossini G; Wagenlehner FM; Mirone V; Bjerklund Johansen TE; Pickard R; Bartoletti R
Eur Urol; 2016 Feb; 69(2):276-83. PubMed ID: 26001610
[TBL] [Abstract][Full Text] [Related]
22. Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study.
Al Muqati H; Al Turaiki A; Al Dhahri F; Al Enazi H; Althemery A
J Infect Public Health; 2021 Mar; 14(3):306-310. PubMed ID: 33618274
[TBL] [Abstract][Full Text] [Related]
23. [Perioperative antibiotic prophylaxis in radical retropubic prostatectomy: a randomised pilot study of perioperative and postoperative administration].
Schenck M; Luetzke A; Ruebben H; Schneider T
Aktuelle Urol; 2011 Jan; 42(1):38-45. PubMed ID: 21267804
[TBL] [Abstract][Full Text] [Related]
24. [Piperacillin/tazobactam plus amikacin vs. piperacilin/tazobactam: treatment for children with febrile neutropenia].
Pacheco-Rosas DO; Peregrino-Bejarano L; López-Aguilar JE; Juan-Shum L; Miranda-Novales MG
Rev Med Inst Mex Seguro Soc; 2019 Jul; 57(2):65-73. PubMed ID: 31617992
[TBL] [Abstract][Full Text] [Related]
25. Extended Versus Narrow-spectrum Antibiotics in the Management of Uncomplicated Appendicitis in Children: A Propensity-matched Comparative Effectiveness Study.
Cameron DB; Melvin P; Graham DA; Glass CC; Serres SK; Kronman MP; Saito JM; Rangel SJ
Ann Surg; 2018 Jul; 268(1):186-192. PubMed ID: 28654543
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
[TBL] [Abstract][Full Text] [Related]
27. Pediatric drug utilization evaluation of cefepime and piperacillin/tazobactam.
Prasopchoknapaporn P; Boonsathorn S; Techasaensiri C; Chaisavaneeyakorn S; Apiwattanakul N
Pediatr Int; 2022 Jan; 64(1):e15276. PubMed ID: 36257611
[TBL] [Abstract][Full Text] [Related]
28. Effect of restricting piperacillin/tazobactam prescription on rates of antimicrobial resistance in gram-negative bacteria and antibiotic consumption.
Oh J; Park SY; Lee JS; Lee SH
Eur J Clin Microbiol Infect Dis; 2023 Jan; 42(1):53-60. PubMed ID: 36378363
[TBL] [Abstract][Full Text] [Related]
29. Evaluating vancomycin and piperacillin-tazobactam in ED patients with severe sepsis and septic shock.
Le C; Chu F; Dunlay R; Villar J; Fedullo P; Wardi G
Am J Emerg Med; 2018 Aug; 36(8):1380-1385. PubMed ID: 29321120
[TBL] [Abstract][Full Text] [Related]
30. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
[TBL] [Abstract][Full Text] [Related]
31. AmpC beta-lactamases in Klebsiella pneumoniae: An emerging threat to the paediatric patients.
Younas S; Ejaz H; Zafar A; Ejaz A; Saleem R; Javed H
J Pak Med Assoc; 2018 Jun; 68(6):893-897. PubMed ID: 30325907
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem.
Holsen MR; Wardlow LC; Bazan JA; Fussner LA; Coe KE; Elefritz JL
Int J Antimicrob Agents; 2019 Dec; 54(6):824-828. PubMed ID: 31319191
[TBL] [Abstract][Full Text] [Related]
33. Is therapeutic drug monitoring really helpful for managing piperacillin/tazobactam therapy in critically ill patients?
Novy E; François T; Luc A; Pape E; Scala-Bertola J
Intensive Care Med; 2022 Nov; 48(11):1676-1678. PubMed ID: 35943572
[No Abstract] [Full Text] [Related]
34. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
Chen GJ; Pan SC; Foo J; Morel C; Chen WT; Wang JT
J Microbiol Immunol Infect; 2019 Oct; 52(5):807-815. PubMed ID: 31029529
[TBL] [Abstract][Full Text] [Related]
35. Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults.
Chen D; Ren H; Zhao Y
JAMA; 2024 Feb; 331(8):708-709. PubMed ID: 38411651
[No Abstract] [Full Text] [Related]
36. Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults.
Chanderraj R; Dickson RP; Sjoding MW
JAMA; 2024 Feb; 331(8):707-708. PubMed ID: 38411650
[No Abstract] [Full Text] [Related]
37. Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults.
Dequidt T; Markowicz S; Coussement J
JAMA; 2024 Feb; 331(8):708. PubMed ID: 38411649
[No Abstract] [Full Text] [Related]
38. Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults-Reply.
Qian ET; Semler MW; Rice TW
JAMA; 2024 Feb; 331(8):709-710. PubMed ID: 38411646
[No Abstract] [Full Text] [Related]
39. Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis.
Yoshihiro S; Taito S
Intensive Care Med; 2022 Jun; 48(6):770-771. PubMed ID: 35182165
[No Abstract] [Full Text] [Related]
40. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
Cojutti PG; Morandin E; Baraldo M; Pea F
Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
